Surface Oncology

Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune evasion.

Surface Oncology headquartered in United States, North America, operates in the Biotechnology, Life Science, Health Care, Oncology sector. The company focuses on Biotechnology and has secured $5.7B in funding across 64 round(s). With a team of 51-100 employees, Surface Oncology is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Surface Oncology, raised $35.0M. Discover more about their projects, partnerships, and impact on our platform.